Ardelyx (ARDX) vs MoonLake Immunotherapeutics (MLTX)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
MoonLake Immunotherapeutics (MLTX) has outperformed Ardelyx (ARDX) over the past year, gaining 16.3% versus a loss of 35.4%. Over five years, ARDX leads with a +202.8% price change compared with +6.7% for MLTX. MoonLake Immunotherapeutics is the larger company by market cap ($900.4 million vs $844.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARDX | MLTX |
|---|---|---|
| Share price | $3.27 | $10.58 |
| Market cap | $844.27M | $900.43M |
| 1-day change | +0.31% | -1.76% |
| YTD return | -43.91% | -19.73% |
| 1-year return | -35.38% | +16.26% |
| 5-year return | +202.78% | +6.65% |
| Forward P/E | 11.26 | — |
| EPS (TTM) | $-0.23 | $-3.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $8.40 | $23.29 |
| 52-week low | $3.18 | $8.80 |
| Distance from 52-week high | -61.07% | -54.57% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +294.50% | +169.75% |
| Average volume | 4.17M | 1.47M |
| Shares outstanding | 258.19M | 85.11M |
| Employees | 489 | 130 |
| Sector | Healthcare | Health Care |
| Industry | Biotechnology | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- MLTX has outperformed ARDX by 51.6 percentage points over the past year.
- The two companies sit in different sectors: Ardelyx in Healthcare and MoonLake Immunotherapeutics in Health Care.
About Ardelyx
ARDX stock →Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally.
Healthcare · Biotechnology · 489 employees
About MoonLake Immunotherapeutics
MLTX stock →MoonLake Immunotherapeutics, a clinical-stage biotechnology company, focuses on developing therapies for inflammatory skin and joint diseases. It develops Sonelokimab, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody for the treatment of inflammatory diseases in dermatology and rheumatology, as well as for hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, palmoplantar pustulosis, and psoriasis.
Health Care · Biotechnology: Pharmaceutical Preparations · 130 employees
ARDX vs MLTX FAQ
Which is bigger, Ardelyx or MoonLake Immunotherapeutics?
MoonLake Immunotherapeutics (MLTX) is larger, with a market capitalization of $900.43M compared with $844.27M for Ardelyx (ARDX).
Which stock has performed better over the past year, ARDX or MLTX?
MLTX returned +16.26% over the past 12 months, compared with -35.38% for ARDX (price return, excluding dividends). Past performance does not predict future results.
Are Ardelyx and MoonLake Immunotherapeutics in the same industry?
No. Ardelyx is in the Healthcare sector, while MoonLake Immunotherapeutics is in Health Care.